- Home
- Media Center
- Press releases
- Financial
Financial
Johnson & Johnson Reports Q2 2021 Results
· Strong sales growth of 27.1% to $23.3 Billion in Second Quarter 2021 with operational growth of 23.0%* and adjusted operational growth of 23.8%* · EPS of $2.35 increased 72.8% in Second Quarter 2021 and adjusted EPS of $2.48 increased 48.5%* · Company increasing 2021 Full-Year guidance for sales and EPS
Johnson & Johnson Reports 2021 First-Quarter Results
• 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%* • 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%* • Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint
Johnson & Johnson to Participate in the BofA Securities Virtual 2021 Healthcare Conference
New Brunswick, NJ (April 12th, 2021) -- Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Virtual 2021 Healthcare Conference on Tuesday, May 11th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time). This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com. A webcast and podcast replay will be available approximately 48 hours after the live webcast. ###